

Anna Teti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5213677/publications.pdf>

Version: 2024-02-01

102
papers

7,403
citations

66250

44
h-index

64407

83
g-index

104
all docs

104
docs citations

104
times ranked

9761
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcriptomic and bioinformatic analysis of Clcn7-dependent Autosomal Dominant Osteopetrosis type 2. Preclinical and clinical implications. <i>Bone</i> , 2021, 144, 115828.	1.4	3
2	Extra-skeletal manifestations in mice affected by Clcn7-dependent autosomal dominant osteopetrosis type 2 clinical and therapeutic implications. <i>Bone Research</i> , 2019, 7, 17.	5.4	12
3	Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry. <i>British Journal of Cancer</i> , 2019, 121, 157-171.	2.9	59
4	Isolation and Generation of Osteoclasts. <i>Methods in Molecular Biology</i> , 2019, 1914, 3-19.	0.4	7
5	Osteoblasts Regulate Angiogenesis in Response to Mechanical Unloading. <i>Calcified Tissue International</i> , 2019, 104, 344-354.	1.5	12
6	Congenital disorders of bone and blood. <i>Bone</i> , 2019, 119, 71-81.	1.4	13
7	RNA interference therapy for autosomal dominant osteopetrosis type 2. Towards the preclinical development. <i>Bone</i> , 2018, 110, 343-354.	1.4	20
8	Osteoblast-Derived Extracellular Vesicles Are Biological Tools for the Delivery of Active Molecules to Bone. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 517-533.	3.1	105
9	Osteopetroses, emphasizing potential approaches to treatment. <i>Bone</i> , 2017, 102, 50-59.	1.4	53
10	The "love-hate" relationship between osteoclasts and bone matrix. <i>Matrix Biology</i> , 2016, 52-54, 176-190.	1.5	38
11	Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e248.	2.3	21
12	Recent Advances in Mesenchymal Stem Cell Immunomodulation: The Role of Microvesicles. <i>Cell Transplantation</i> , 2015, 24, 133-149.	1.2	91
13	Biotechnological approach for systemic delivery of membrane Receptor Activator of NF- κ B Ligand (RANKL) active domain into the circulation. <i>Biomaterials</i> , 2015, 46, 58-69.	5.7	23
14	The β 1 binding domain of chondroadherin inhibits breast cancer-induced bone metastases and impairs primary tumour growth: A preclinical study. <i>Cancer Letters</i> , 2015, 358, 67-75.	3.2	13
15	Lipocalin 2: A New Mechanoresponding Gene Regulating Bone Homeostasis. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 357-368.	3.1	76
16	Reprint of: The Great Beauty of the osteoclast. <i>Archives of Biochemistry and Biophysics</i> , 2014, 561, 13-21.	1.4	37
17	Differentially expressed genes in autosomal dominant osteopetrosis type II osteoclasts reveal known and novel pathways for osteoclast biology. <i>Laboratory Investigation</i> , 2014, 94, 275-285.	1.7	20
18	Bone, a dynamic and integrating tissue. <i>Archives of Biochemistry and Biophysics</i> , 2014, 561, 1-2.	1.4	13

#	ARTICLE	IF	CITATIONS
19	The C-Terminal Domain of Chondroadherin: A New Regulator of Osteoclast Motility Counteracting Bone Loss. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1833-1846.	3.1	17
20	Kinome profiling of osteoblasts on hydroxyapatite opens new avenues on biomaterial cell signaling. <i>Biotechnology and Bioengineering</i> , 2014, 111, 1900-1905.	1.7	42
21	Deregulation of the IL-1 β axis in chronic recurrent multifocal osteomyelitis. <i>Pediatric Rheumatology</i> , 2014, 12, 30.	0.9	71
22	<i>CLCN7</i> and <i>TCIRG1</i> Mutations Differentially Affect Bone Matrix Mineralization in Osteopetrotic Individuals. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 982-991.	3.1	38
23	Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. <i>BMC Cancer</i> , 2014, 14, 154.	1.1	92
24	The Great Beauty of the osteoclast. <i>Archives of Biochemistry and Biophysics</i> , 2014, 558, 70-78.	1.4	173
25	Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models. <i>Bone</i> , 2014, 59, 66-75.	1.4	36
26	Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1912-1924.	3.1	21
27	Role of Stem Cell Niche in the Development of Bone Metastases (An Update). , 2013, , 229-238.		0
28	Mechanisms of osteoclast-dependent bone formation. <i>BoneKEy Reports</i> , 2013, 2, 449.	2.7	70
29	Osteoclast Determinants and Implications for Therapy. , 2013, , 121-130.		0
30	Haematopoietic Stem Cell Transplantation in Autosomal Recessive Osteopetrosis. , 2013, , 267-288.		2
31	Osteoclasts and hematopoiesis. <i>BoneKEy Reports</i> , 2012, 1, 46.	2.7	18
32	NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains. <i>Molecular Biology of the Cell</i> , 2012, 23, 2028-2040.	0.9	19
33	Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2387-2398.	3.1	24
34	c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling. <i>Nature Communications</i> , 2012, 3, 630.	5.8	93
35	The Physiology and Pathophysiology of the Osteoclast. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2012, 10, 71-97.	1.3	14
36	Novel C16orf57 mutations in patients with Poikiloderma with Neutropenia: bioinformatic analysis of the protein and predicted effects of all reported mutations. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 7.	1.2	48

#	ARTICLE	IF	CITATIONS
37	Bone Development: Overview of Bone Cells and Signaling. <i>Current Osteoporosis Reports</i> , 2011, 9, 264-273.	1.5	103
38	Mechanisms inducing low bone density in duchenne muscular dystrophy in mice and humans. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1891-1903.	3.1	116
39	Committed osteoclast precursors colonize the bone and improve the phenotype of a mouse model of autosomal recessive osteopetrosis. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 106-113.	3.1	11
40	Design of novel three-phase PCL/TZâ€“HA biomaterials for use in bone regeneration applications. <i>Journal of Materials Science: Materials in Medicine</i> , 2010, 21, 2569-2581.	1.7	30
41	Receptor Activator of NF-Î²B Ligand Enhances Breast Cancerâ€“Induced Osteolytic Lesions through Upregulation of Extracellular Matrix Metalloproteinase Inducer/CD147. <i>Cancer Research</i> , 2010, 70, 6150-6160.	0.4	54
42	Expanding the role of Src and protein-tyrosine phosphatases balance in modulating osteoblast metabolism: Lessons from mice. <i>Biochimie</i> , 2010, 92, 327-332.	1.3	44
43	Insulin Signaling in Osteoblasts Integrates Bone Remodeling and Energy Metabolism. <i>Cell</i> , 2010, 142, 296-308.	13.5	957
44	The central role of the skeleton in chronic diseases. <i>Archives of Biochemistry and Biophysics</i> , 2010, 503, 1.	1.4	3
45	The glycosaminoglycan-binding domain of PRELP acts as a cell typeâ€“specific NF-Î²B inhibitor that impairs osteoclastogenesis. <i>Journal of Cell Biology</i> , 2009, 187, 669-683.	2.3	72
46	Global transcriptome analysis in mouse calvarial osteoblasts highlights sets of genes regulated by modeled microgravity and identifies a â€œmechanoresponsive osteoblast gene signatureâ€“. <i>Journal of Cellular Biochemistry</i> , 2009, 107, 240-252.	1.2	63
47	Impaired gastric acidification negatively affects calcium homeostasis and bone mass. <i>Nature Medicine</i> , 2009, 15, 674-681.	15.2	172
48	Î²-Arrestin2 Regulates RANKL and Ephrins Gene Expression in Response to Bone Remodeling in Mice. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 775-784.	3.1	37
49	Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. <i>Bone</i> , 2009, 44, 11-16.	1.4	208
50	Kinase-Dependent and -Independent Roles of EphA2 in the Regulation of Prostate Cancer Invasion and Metastasis. <i>American Journal of Pathology</i> , 2009, 174, 1492-1503.	1.9	96
51	A New Heterozygous Mutation (R714C) of the Osteopetrosis Gene, <i>Pleckstrin Homolog Domain Containing Family M (With Run Domain) Member 1 (PLEKHM1)</i> , Impairs Vesicular Acidification and Increases TRACP Secretion in Osteoclasts. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 380-391.	3.1	69
52	A Six-Gene Signature Predicting Breast Cancer Lung Metastasis. <i>Cancer Research</i> , 2008, 68, 6092-6099.	0.4	131
53	Osteoclast receptors and signaling. <i>Archives of Biochemistry and Biophysics</i> , 2008, 473, 147-160.	1.4	83
54	Bone remodeling: Facts and perspectives. <i>Archives of Biochemistry and Biophysics</i> , 2008, 473, 97.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Genetics, pathogenesis and complications of osteopetrosis. <i>Bone</i> , 2008, 42, 19-29.	1.4	240
56	Inhibition of Protein Kinase c-Src as a Therapeutic Approach for Cancer and Bone Metastases. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2008, 8, 342-349.	0.9	69
57	Osteopenia, decreased bone formation and impaired osteoblast development in <i>Sox4</i> heterozygous mice. <i>Journal of Cell Science</i> , 2007, 120, 2785-2795.	1.2	80
58	Modeled microgravity stimulates osteoclastogenesis and bone resorption by increasing osteoblast RANKL/OPG ratio. <i>Journal of Cellular Biochemistry</i> , 2007, 100, 464-473.	1.2	93
59	Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. <i>Nature Genetics</i> , 2007, 39, 960-962.	9.4	346
60	Bone metastasis: pathogenesis and therapeutic implications. <i>Clinical and Experimental Metastasis</i> , 2007, 24, 599-608.	1.7	132
61	Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. <i>Journal of Clinical Investigation</i> , 2007, 117, 919-930.	3.9	204
62	Impaired skeletal development in interleukin-6 transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. <i>Arthritis and Rheumatism</i> , 2006, 54, 3551-3563.	6.7	271
63	Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles. <i>Journal of Endocrinology</i> , 2006, 191, 287-299.	1.2	45
64	Inhibition of Protein Kinase c-Src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice: Implications for Therapy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 161-172.	1.3	126
65	Modulation of human estrogen receptor β promoter by a protein kinase C/c-Src-dependent mechanism in osteoblast-like cells. <i>Journal of Molecular Endocrinology</i> , 2006, 37, 489-502.	1.1	12
66	Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. <i>Endocrine-Related Cancer</i> , 2006, 13, 197-210.	1.6	79
67	Polymorphisms of the CLCN7 Gene Are Associated With BMD in Women. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1960-1967.	3.1	31
68	A novel protein kinase C δ -dependent signal to ERK1/2 activated by $\alpha 3 \beta 1$ integrin in osteoclasts and in Chinese hamster ovary (CHO) cells. <i>Journal of Cell Science</i> , 2005, 118, 3263-3275.	1.2	60
69	Imbalance of Osteoclastogenesis-Regulating Factors in Patients With Celiac Disease. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1112-1121.	3.1	91
70	Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. <i>Bone</i> , 2004, 34, 65-79.	1.4	67
71	In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human breast cancer cells. <i>Bone</i> , 2004, 34, 697-709.	1.4	27
72	Interaction of estrogen receptor β with protein kinase C δ and c-Src in osteoblasts during differentiation. <i>Bone</i> , 2004, 34, 100-111.	1.4	43

#	ARTICLE	IF	CITATIONS
73	Chloride Channel CLCN7 Mutations Are Responsible for Severe Recessive, Dominant, and Intermediate Osteopetrosis. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 1740-1747.	3.1	202
74	Genotype-Phenotype Relationship in Human ATP6i-Dependent Autosomal Recessive Osteopetrosis. <i>American Journal of Pathology</i> , 2003, 162, 57-68.	1.9	97
75	Osteopontin Modulates Prostate Carcinoma Invasive Capacity through RGD-Dependent Upregulation of Plasminogen Activators. <i>Biological Chemistry</i> , 2002, 383, 229-234.	1.2	33
76	Characterization of the osteoblast-like cell phenotype under microgravity conditions in the NASA-approved rotating wall vessel bioreactor (RWV). <i>Journal of Cellular Biochemistry</i> , 2002, 85, 167-179.	1.2	90
77	Collagen VII expression in glomerular sclerosis. <i>Journal of Pathology</i> , 2001, 195, 383-390.	2.1	16
78	Apparent Cure of a Newborn with Malignant Osteopetrosis Using Prednisone Therapy. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 2356-2360.	3.1	23
79	Osteoblast-derived TGF- β 1 modulates matrix degrading protease expression and activity in prostate cancer cells. <i>International Journal of Cancer</i> , 2000, 85, 407-415.	2.3	59
80	Osteoblast-derived TGF- β 1 modulates matrix degrading protease expression and activity in prostate cancer cells. , 2000, 86, 888-888.		16
81	Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone Formation. <i>Journal of Cell Biology</i> , 2000, 151, 311-320.	2.3	275
82	Immediate cell signal induced by laminin in rat Sertoli cells. <i>Matrix Biology</i> , 2000, 19, 11-18.	1.5	15
83	Oligodeoxynucleotide Targeted to the α v Gene Inhibits α v Integrin Synthesis, Impairs Osteoclast Function, and Activates Intracellular Signals to Apoptosis. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 1867-1879.	3.1	26
84	Mechanisms of Osteoclast Dysfunction in Human Osteopetrosis: Abnormal Osteoclastogenesis and Lack of Osteoclast-Specific Adhesion Structures. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 2107-2117.	3.1	43
85	Osteoclast Isolation: New Developments and Methods. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 1251-1252.	3.1	11
86	Osteoblast conditioned media contain TGF- β 1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. , 1999, 81, 395-403.		78
87	A Novel Calcium Sensor Stimulating Inositol Phosphate Formation and $[Ca^{2+}]_i$ Signaling Expressed by GCT23 Osteoclast-Like Cells. <i>Proceedings of the Association of American Physicians</i> , 1999, 111, 70-81.	2.1	35
88	Colony Stimulating Factor-1-Induced Osteoclast Spreading Depends on Substrate and Requires the Vitronectin Receptor and the c-src Proto-Oncogene. <i>Journal of Bone and Mineral Research</i> , 1998, 13, 50-58.	3.1	42
89	Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. , 1998, 77, 82-93.		52
90	Protein Kinase C Modulates Estrogen Receptors in Differentiated Osteoblastic Cells In Vitro. <i>Steroids</i> , 1998, 63, 352-354.	0.8	16

#	ARTICLE	IF	CITATIONS
91	Tartronates: A New Generation of Drugs Affecting Bone Metabolism. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 972-981.	3.1	42
92	Transforming growth factor- β^2 enhances adhesion of melanoma cells to the endothelium in vitro. , 1997, 72, 1013-1020.		28
93	Calcitonin Increases Cytosolic Free Calcium Concentration via Capacitative Calcium Influx. <i>Journal of Biological Chemistry</i> , 1995, 270, 16666-16670.	1.6	27
94	Translocation of protein kinase C isoenzymes by elevated extracellular Ca^{2+} concentration in cells from a human giant cell tumor of bone. <i>Bone</i> , 1995, 17, 175-183.	1.4	19
95	Osteoblast-osteoclast relationships in bone resorption: Osteoblasts enhance osteoclast activity in a serum-free co-culture system. <i>Biochemical and Biophysical Research Communications</i> , 1991, 179, 634-640.	1.0	29
96	Parathyroid hormone binding to cultured avian osteoclasts. <i>Biochemical and Biophysical Research Communications</i> , 1991, 174, 1217-1222.	1.0	73
97	Beta ₃ Subunit of Vitronectin Receptor is Present in Osteoclast Adhesion Structures and Not in Other Monocyte-Macrophage Derived Cells. <i>Connective Tissue Research</i> , 1989, 20, 143-149.	1.1	40
98	Immunocytochemical distribution of extracellular matrix receptors in human osteoclasts: $\alpha^2\beta_3$ integrin is colocalized with vinculin and talin in the podosomes of osteoclastoma giant cells. <i>Experimental Cell Research</i> , 1989, 182, 645-652.	1.2	197
99	The effects of parathyroid hormone or 1,25-dihydroxyvitamin D3 on monocyte-osteoclast fusion. <i>Calcified Tissue International</i> , 1988, 42, 302-308.	1.5	14
100	Metaplastic Bone Tissue in Tympanosclerosis. <i>Acta Oto-Laryngologica</i> , 1983, 95, 554-559.	0.3	7
101	Isolated osteoclasts in primary culture: first observations on structure and survival in culture media. <i>Anatomy and Embryology</i> , 1982, 165, 405-413.	1.5	117
102	Modulation of Estrogen Receptor Levels in Mouse Uterus by Protein Kinase C Isoenzymes*This work was supported by funds from the NIEHS Intramural Program (to K.S.K. and W.C.W.) and the Department of Psychiatry and Behavioral Sciences at Duke University Medical Center (to W.C.W.).. , 0, .		4